KRAS and non-small cell lung carcinoma: Accordingly, a recent study (JBR.10) showed that mutations of K-Ras gene were neither prognostic for survival nor predictive of a differential benefit from adjuvant chemotherapy in stage IB and II NSCLC (Tsao et al, 2007).